HHM Wealth Advisors LLC Reduces Position in Thermo Fisher Scientific Inc. (NYSE:TMO)

HHM Wealth Advisors LLC trimmed its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 20.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 125 shares of the medical research company’s stock after selling 32 shares during the quarter. HHM Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $66,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. Linden Thomas Advisory Services LLC increased its holdings in Thermo Fisher Scientific by 8.8% in the third quarter. Linden Thomas Advisory Services LLC now owns 1,546 shares of the medical research company’s stock valued at $783,000 after buying an additional 125 shares during the last quarter. Avestar Capital LLC grew its holdings in shares of Thermo Fisher Scientific by 15.6% during the third quarter. Avestar Capital LLC now owns 1,135 shares of the medical research company’s stock valued at $575,000 after purchasing an additional 153 shares during the last quarter. Harbor Capital Advisors Inc. grew its holdings in shares of Thermo Fisher Scientific by 17.7% during the third quarter. Harbor Capital Advisors Inc. now owns 1,241 shares of the medical research company’s stock valued at $628,000 after purchasing an additional 187 shares during the last quarter. Steward Financial Group LLC bought a new position in shares of Thermo Fisher Scientific during the third quarter valued at approximately $73,000. Finally, Commonwealth Equity Services LLC grew its holdings in shares of Thermo Fisher Scientific by 0.8% during the third quarter. Commonwealth Equity Services LLC now owns 99,703 shares of the medical research company’s stock valued at $50,467,000 after purchasing an additional 835 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Thermo Fisher Scientific Price Performance

Shares of NYSE:TMO opened at $573.60 on Monday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.33 and a current ratio of 1.70. The company has a market capitalization of $218.95 billion, a PE ratio of 36.79, a price-to-earnings-growth ratio of 2.41 and a beta of 0.80. Thermo Fisher Scientific Inc. has a one year low of $415.60 and a one year high of $603.82. The stock has a fifty day moving average of $573.60 and a 200-day moving average of $530.40.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, April 24th. The medical research company reported $5.11 EPS for the quarter, topping the consensus estimate of $4.70 by $0.41. Thermo Fisher Scientific had a net margin of 14.20% and a return on equity of 18.45%. The firm had revenue of $10.35 billion for the quarter, compared to the consensus estimate of $10.14 billion. As a group, equities analysts anticipate that Thermo Fisher Scientific Inc. will post 21.56 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The firm also recently declared a quarterly dividend, which was paid on Monday, April 15th. Investors of record on Friday, March 15th were given a $0.39 dividend. This represents a $1.56 annualized dividend and a yield of 0.27%. The ex-dividend date of this dividend was Thursday, March 14th. This is a positive change from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. Thermo Fisher Scientific’s dividend payout ratio is 10.01%.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at $7,250,362. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, Director Debora L. Spar sold 164 shares of Thermo Fisher Scientific stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $546.97, for a total value of $89,703.08. Following the completion of the transaction, the director now owns 1,207 shares in the company, valued at $660,192.79. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 14,566 shares of Thermo Fisher Scientific stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the transaction, the senior vice president now owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 50,277 shares of company stock valued at $28,513,384. 0.34% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several research firms have recently commented on TMO. The Goldman Sachs Group upped their target price on Thermo Fisher Scientific from $550.00 to $640.00 and gave the company a “buy” rating in a report on Wednesday, April 10th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Thermo Fisher Scientific in a research report on Monday, January 8th. Citigroup started coverage on Thermo Fisher Scientific in a research report on Monday, March 18th. They set a “neutral” rating and a $620.00 price objective for the company. JPMorgan Chase & Co. boosted their price objective on Thermo Fisher Scientific from $600.00 to $650.00 and gave the stock an “overweight” rating in a research report on Thursday. Finally, Barclays upped their target price on Thermo Fisher Scientific from $590.00 to $615.00 and gave the stock an “equal weight” rating in a research report on Thursday. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and a consensus price target of $606.76.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.